Prevalence and clinical impact of JAK2-CHIP: Association with Parkinsonism and hematologic changes in a population cohort
Related Experiment Video
Updated: Jan 15, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Cih-En Huang1, Yi-Yang Chen1, Chang-Hsien Lu2
1Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Background:
JAK2V617F-associated clonal hematopoiesis of indeterminate potential (JAK2-CHIP) has been implicated in cardiovascular disease through inflammatory and thrombotic mechanisms. However, its role in microthromboembolism-related events (miTE-REs), particularly neurodegenerative disorders, remains underexplored.
Methods:
In this retrospective cohort study, we screened 1768 individuals from a health screening population for JAK2V617F using a high-sensitivity qCAST-Duplex PCR assay. To enhance efficiency, we employed a pooled PCR strategy: genomic DNA from 10 samples was combined per reaction. Given the assay's detection limit of 0.01 %, this approach allowed identification of any individual sample with a mutant allele burden (AB) > 0.1 %. Positive pools were deconvoluted and tested individually. Clinical data were analyzed to assess associations between JAK2-CHIP and miTE-REs, including Parkinsonism, dementia, Alzheimer's disease, heart failure, and avascular necrosis. Temporal changes in AB were evaluated in participants with serial blood samples.
Results:
JAK2-CHIP was identified in 32 individuals (1.8 %), with prevalence increasing with age. Carriers had a significantly higher prevalence of Parkinsonism than non-carriers (15.6 % vs. 6.3 %, p = 0.035). Carriers with AB ≥1 % had elevated platelet and basophil counts, suggesting subclinical myeloid lineage activation. Among those with serial data, 22.7 % showed clonal expansion, though none developed hematologic malignancy.
Conclusion:
JAK2-CHIP is associated with increased prevalence of Parkinsonism in otherwise healthy individuals, possibly via microvascular or inflammatory pathways. Elevated platelet and basophil counts among carriers support early functional consequences of this mutation. These findings highlight the clinical relevance of detecting JAK2-CHIP in general populations and underscore its potential as a biomarker for neurologic risk stratification and longitudinal monitoring.
Insights
Clonal hematopoiesis (JAK2-CHIP) is linked to a higher risk of Parkinsonism in healthy individuals. This finding suggests JAK2-CHIP may be a biomarker for neurological conditions.
Area of Science:
- Hematology
- Neurology
- Genetics
Background:
- JAK2V617F-associated clonal hematopoiesis of indeterminate potential (JAK2-CHIP) is linked to cardiovascular disease.
- Its role in microthromboembolism-related events (miTE-REs), especially neurodegenerative disorders, is not well understood.
Purpose of the Study:
- To investigate the association between JAK2-CHIP and miTE-REs, including neurodegenerative conditions.
- To assess the prevalence and clinical implications of JAK2-CHIP in a health screening population.
Main Methods:
- Retrospective cohort study of 1768 individuals screened for JAK2V617F using high-sensitivity pooled PCR.
- Clinical data analysis to correlate JAK2-CHIP with Parkinsonism, dementia, Alzheimer's disease, heart failure, and avascular necrosis.
- Evaluation of temporal changes in mutant allele burden (AB) in participants with serial samples.
Main Results:
- JAK2-CHIP identified in 1.8% of individuals, with prevalence increasing with age.
- JAK2-CHIP carriers showed a significantly higher prevalence of Parkinsonism (15.6% vs. 6.3%, p=0.035).
- Carriers with AB ≥1% had elevated platelet and basophil counts, indicating subclinical myeloid activation; 22.7% showed clonal expansion without malignancy.
Conclusions:
- JAK2-CHIP is associated with increased Parkinsonism prevalence in healthy individuals, potentially through microvascular or inflammatory pathways.
- Elevated blood cell counts in carriers suggest early functional consequences of JAK2-CHIP.
- Detecting JAK2-CHIP is clinically relevant for risk stratification and monitoring of neurological conditions.
More Related Videos
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
14:45Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
01:15Parkinson's Disease: Overview
01:08Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
01:29Therapeutic Drug Monitoring: Affecting Factors
01:24Chronic Kidney Disease II: Clinical Manifestations